Literature DB >> 12621118

Increased fibronectin expression in sturge-weber syndrome fibroblasts and brain tissue.

Anne M Comi1, Piper Hunt, Marquis P Vawter, Carlos A Pardo, Kevin G Becker, Jonathan Pevsner.   

Abstract

Sturge-Weber syndrome (SWS) is a neurocutaneous disorder that presents with a facial port-wine stain and a leptomeningeal angioma. Fibronectin expression regulates angiogenesis and vasculogenesis and participates in brain tissue responses to ischemia and seizures. We therefore hypothesized that abnormal gene expression of fibronectin and other extracellular matrix genes would be found in SWS brain tissue and SWS port-wine skin fibroblasts. Fibronectin gene and protein expression from port-wine-derived fibroblasts were compared with that from normal skin-derived fibroblasts of four individuals with SWS using microarrays, reverse transcriptase-PCR, Western analysis, and immunocytochemistry. Fibronectin gene and/or protein expression from eight SWS surgical brain samples was compared with that in two surgical epilepsy brain samples and six postmortem brain samples using microarrays, reverse transcriptase-PCR, and Western analysis. The gene expression of fibronectin was significantly increased (p < 0.05) in the SWS port-wine-derived fibroblasts compared with that of fibroblasts from SWS normal skin. A trend for increased protein levels of fibronectin in port-wine fibroblasts was found by Western analysis. No difference in the pattern of fibronectin staining was detected. The gene expression of fibronectin was significantly increased (p < 0.05), and a trend for increased fibronectin protein expression was found in the SWS surgical brain samples compared with the postmortem controls. These results suggest a potential role for fibronectin in the pathogenesis of SWS and in the brain's response to chronic ischemic injury in SWS. The reproducible differences in fibronectin gene expression between the SWS port-wine-derived fibroblasts and the SWS normal skin-derived fibroblasts are consistent with the presence of a hypothesized somatic mutation underlying SWS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12621118     DOI: 10.1203/01.PDR.0000058921.54071.19

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

1.  Cell proliferation and oxidative stress pathways are modified in fibroblasts from Sturge-Weber syndrome patients.

Authors:  Shilpa D Kadam; Marjan Gucek; Robert N Cole; Paul A Watkins; Anne M Comi
Journal:  Arch Dermatol Res       Date:  2012-03-10       Impact factor: 3.017

2.  Sturge-Weber syndrome (encephalotrigeminal or leptomeningeal angiomatosis).

Authors:  J M S Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11       Impact factor: 10.154

Review 3.  Sturge-Weber syndrome.

Authors:  C Di Rocco; G Tamburrini
Journal:  Childs Nerv Syst       Date:  2006-07-06       Impact factor: 1.475

4.  Behavioral manifestations of sturge-weber syndrome: a case report.

Authors:  Vishal Madaan; Vijay Dewan; Sriram Ramaswamy; Ashish Sharma
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

5.  Detection of RASA1 mutations in patients with sporadic Sturge-Weber syndrome.

Authors:  Qin Zhou; Jia-wei Zheng; Xiu-juan Yang; Hui-jun Wang; Duan Ma; Zhong-ping Qin
Journal:  Childs Nerv Syst       Date:  2010-09-07       Impact factor: 1.475

6.  Microarray analysis of port wine stains before and after pulsed dye laser treatment.

Authors:  Vivian T Laquer; Peter A Hevezi; Huguette Albrecht; Tina S Chen; Albert Zlotnik; Kristen M Kelly
Journal:  Lasers Surg Med       Date:  2013-02       Impact factor: 4.025

7.  A child with Apert syndrome and Sturge-Weber syndrome: could fibronectin or the RAS/MAPK signaling pathway be the connection?

Authors:  Ai Peng Tan; Wui Khean Chong
Journal:  Childs Nerv Syst       Date:  2018-02-23       Impact factor: 1.475

8.  Sturge-Weber syndrome type II treated with PDL 595 nm laser.

Authors:  Joanna Kowalska-Brocka; Maciej Brocki; Sebastian Uczniak; Kamila Uczniak; Andrzej Kaszuba; Piotr Jurowski
Journal:  Postepy Dermatol Alergol       Date:  2015-02-03       Impact factor: 1.837

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.